46results about How to "Increase entry" patented technology

A clip for holding a first section of fiber optic cable to a second section of fiber optic cable is useful in forming a weave pattern in a fiber optic security fence. The fiber optic security fence is constructed by forming a zigzag pattern in a fiber optic cable and attaching this pattern to an existing barrier fence, e.g. a galvanized chain-link fence. Clips are provided to hold portions of the fiber optic cable together in the zigzag pattern. The clips are formed such that, once installed, they are very difficult to remove without cutting, stressing or bending the fiber optic cable sections passing therethrough. Therefore, the clips will prevent intruders from disconnecting the pattern of the fiber optic cable, in order to cut through the barrier fence and gain entry into a secure area.

The present invention uses co-expression of protease inhibitors and protease sensitive therapeutic agents that results in their localized production within the target tissue and inactivation outside of the target tissue, thereby increasing therapeutic activity and reducing the systemic toxicity. Inactivation is also accomplished by engineering protease degradation sites within the therapeutic construct for proteases, preferably those that are under-expressed within the target tissue yet present in non-target tissues within the body, resulting in therapeutic activity within the target tissue and inactivation outside of the target tissue. Novel chimeric proteins secreted by bacteria are also described. The chimeric proteins include chimeric toxins targeted to neoplastic cells and cells of the immune system. Novel combination therapies of these protease inhibitor:chimeric toxin-expressing bacteria together with small-molecule and biologic agents are also described. Non-conjugative bacteria capable of delivering phage / phagemids expression cassettes for DNA and RNA-based therapeutics are also described.

A sensor unit (10) for detecting a gas is configured with a pressure-tight measuring channel (11), with a gas inlet (12) for introducing the gas into the measuring channel, with a gas outlet (13) for removing the gas from the measuring channel, and with a pump unit (14) for evacuating the measuring channel. The measuring channel has a gas sensor (15) for detecting the gas and a heating unit (16) for heating the gas sensor. The sensor unit (10) is configured to be operated in a measuring mode and in a regeneration mode. The measuring channel (11) is evacuated and the gas sensor (15) is heated in the regeneration mode.

The present invention relates to a vehicle comprising a vehicle body, a vehicle door releasably locatable in an access aperture of the vehicle body, a platform forming at least part of the interior floor of the vehicle and being displaceably mounted on the vehicle body adjacent to the door, and means for displacing the platform outwardly and inwardly with respect to the vehicle body through the access aperture when the door is open.

The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compounds (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.

A sensor unit (10) for detecting a gas is configured with a pressure-tight measuring channel (11), with a gas inlet (12) for introducing the gas into the measuring channel, with a gas outlet (13) for removing the gas from the measuring channel, and with a pump unit (14) for evacuating the measuring channel. The measuring channel has a gas sensor (15) for detecting the gas and a heating unit (16) for heating the gas sensor. The sensor unit (10) is configured to be operated in a measuring mode and in a regeneration mode. The measuring channel (11) is evacuated and the gas sensor (15) is heated in the regeneration mode.

The invention is a hydrogen passivation shut down system for a fuel cell power plant (10, 200). During shut down of the plant (10, 200), hydrogen fuel is permitted to transfer between an anode flow path (24, 24′) and a cathode flow path (38, 38′). A controlled-oxidant flow device (209) near an oxygen source (58′) permits a minimal amount of atmospheric oxygen to enter the power plant (200) during shut down to equalize pressure between ambient atmosphere and the flow paths (24′, 28′) and to keep limited atmospheric oxygen entering the power plant (200) through the device (209) as far as possible from fuel cell flow fields (28′, 42′). A non-leaking hydrogen inlet valve (202), a non-leaking cathode exhaust valve (208), and a combined oxidant and fuel exhaust line (206) also minimize penetration of oxygen into the shut down power plant (200).

A brake disk is described that has a friction ring and a disk pot that is connected to the friction ring via connecting elements. On the webs of the friction ring, bearer webs are fashioned into which the connecting elements extend. In addition, the bearer webs are fashioned in such a way that cooling air can flow around them.

In the present specification we describe a new class of compounds, designed to modulate the ability of blood vessels to synthesize NO from L-arginine. In particular we have identified novel compounds which enhance the entry of L-arginine into cells. These compounds improve endothelial function, and thereby have the potential to retard the progression of vascular disease in conditions such as hypertension, heart failure and diabetes. This new class of drugs may also have other potentially, relevant pharmacological actions, including anti-hypertensive and anti-anginal actions.

The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and / or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and / or diseases or disorders that result in conditions in which muscle is adversely affected.